Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14001-

  Jin, Chuan ^a   Yu, Di ^a   Hillerdal, Victoria ^a   Wallgren, AnnaCarin ^a   Karlsson Parra, Alex ^a   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; OKT 3;

ADOPTIVE TRANSFER; ALLOSENSITIZED ALLOGENEIC LYMPHOCYTE; ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL KILLING; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; OXIDATIVE STRESS; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 85015703065     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.1     Document Type: Article

References (41)

1. 1 Rosenberg, SA, Dudley, ME, Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 101:suppl. 2 (2004), 14639–14645.
2. 2 Levine, BL, Bernstein, WB, Connors, M, Craighead, N, Lindsten, T, Thompson, CB, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 159 (1997), 5921–5930.
3. 3 Li, Y, Kurlander, RJ, Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J Transl Med, 8, 2010, 104.
4. 4 Klapper, JA, Thomasian, AA, Smith, DM, Gorgas, GC, Wunderlich, JR, Smith, FO, et al. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J Immunol Methods 345 (2009), 90–99.
5. 5 Ceuppens, JL, Bloemmen, FJ, Van Wauwe, JP, T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc gamma receptors for murine IgG2a and inability to cross-link the T3-Ti complex. J Immunol 135 (1985), 3882–3886.
6. 6 Yang, S, Dudley, ME, Rosenberg, SA, Morgan, RA, A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. J Immunother 33 (2010), 648–658.
7. 7 Kobayashi, H, Tanaka, Y, Yagi, J, Minato, N, Tanabe, K, Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 60 (2011), 1075–1084.
8. 8 Wang, QJ, Hanada, K, Feldman, SA, Zhao, Y, Inozume, T, Yang, JC, Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. J Immunol Methods 366 (2011), 43–51.
9. 9 Gattinoni, L, Klebanoff, CA, Palmer, DC, Wrzesinski, C, Kerstann, K, Yu, Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115 (2005), 1616–1626.
10. 10 Berger, C, Turtle, CJ, Jensen, MC, Riddell, SR, Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 21 (2009), 224–232.
11. 11 Banchereau, J, Steinman, RM, Dendritic cells and the control of immunity. Nature 392 (1998), 245–252.
12. 12 Kaliński, P, Hilkens, CM, Wierenga, EA, Kapsenberg, ML, T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20 (1999), 561–567.
13. 13 Janssen, EM, Lemmens, EE, Wolfe, T, Christen, U, von Herrath, MG, Schoenberger, SP, CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421 (2003), 852–856.
14. 14 Shedlock, DJ, Shen, H, Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300 (2003), 337–339.
15. 15 Ridge, JP, Di Rosa, F, Matzinger, P, A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393 (1998), 474–478.
16. 16 Cella, M, Scheidegger, D, Palmer-Lehmann, K, Lane, P, Lanzavecchia, A, Alber, G, Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184 (1996), 747–752.
17. 17 Lu, Z, Yuan, L, Zhou, X, Sotomayor, E, Levitsky, HI, Pardoll, DM, CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med 191 (2000), 541–550.
18. 18 Williams, MA, Tyznik, AJ, Bevan, MJ, Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441 (2006), 890–893.
19. 19 Kalinski, P, Nakamura, Y, Watchmaker, P, Giermasz, A, Muthuswamy, R, Mailliard, RB, Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res 36 (2006), 137–146.
20. 20 Fernandez, NC, Flament, C, Crépineau, F, Angevin, E, Vivier, E, Zitvogel, L, Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur Cytokine Netw 13 (2002), 17–27.
21. 21 Huang, J, Khong, HT, Dudley, ME, El-Gamil, M, Li, YF, Rosenberg, SA, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28 (2005), 258–267.
22. 22 Fourcade, J, Sun, Z, Benallaoua, M, Guillaume, P, Luescher, IF, Sander, C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207 (2010), 2175–2186.
23. + T-cells via CD27-CD70 interactions. Nat Commun, 3, 2012, 948.
24. 24 Koch, F, Stanzl, U, Jennewein, P, Janke, K, Heufler, C, Kämpgen, E, et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 184 (1996), 741–746.
25. 25 Porter, DL, Levine, BL, Kalos, M, Bagg, A, June, CH, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365 (2011), 725–733.
26. 26 Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 (2013), 1509–1518.
27. 27 Seeger, RC, Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 21 (2011), 229–237.
28. 28 Yu, P, Fu, YX, Tumor-infiltrating T lymphocytes: friends or foes?. Lab Invest 86 (2006), 231–245.
29. 29 Hillerdal, V, Nilsson, B, Carlsson, B, Eriksson, F, Essand, M, T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells. Proc Natl Acad Sci USA 109 (2012), 15877–15881.
30. 30 Li, Y, Liu, S, Hernandez, J, Vence, L, Hwu, P, Radvanyi, L, MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol 184 (2010), 452–465.
31. 31 Bevan, MJ, Helping the CD8(+) T-cell response. Nat Rev Immunol 4 (2004), 595–602.
32. 32 Kawamura, T, Ogawa, Y, Shimozato, O, Ando, T, Nakao, A, Kobata, T, et al. CD70 is selectively expressed on Th1 but not on Th2 cells and is required for Th1-type immune responses. J Invest Dermatol 131 (2011), 1252–1261.
33. 33 Taraban, VY, Rowley, TF, Al-Shamkhani, A, Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J Immunol 173 (2004), 6542–6546.
34. 34 Taraban, VY, Rowley, TF, Tough, DF, Al-Shamkhani, A, Requirement for CD70 in CD4+ Th cell-dependent and innate receptor-mediated CD8+ T cell priming. J Immunol 177 (2006), 2969–2975.
35. 35 Robbins, PF, Dudley, ME, Wunderlich, J, El-Gamil, M, Li, YF, Zhou, J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173 (2004), 7125–7130.
36. 36 Berger, C, Jensen, MC, Lansdorp, PM, Gough, M, Elliott, C, Riddell, SR, Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118 (2008), 294–305.
37. 37 Hendriks, J, Xiao, Y, Borst, J, CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med 198 (2003), 1369–1380.
38. 38 Trinchieri, G, Gerosa, F, Immunoregulation by interleukin-12. J Leukoc Biol 59 (1996), 505–511.
39. 39 Otsuji, M, Kimura, Y, Aoe, T, Okamoto, Y, Saito, T, Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 93 (1996), 13119–13124.
40. 40 Malmberg, KJ, Arulampalam, V, Ichihara, F, Petersson, M, Seki, K, Andersson, T, et al. Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol 167 (2001), 2595–2601.
41. 41 de Visser, KE, Kast, WM, Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 13 (1999), 1188–1199.